`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`___________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________________
`
`
`NOVEN PHARMACEUTICALS, INC.
`AND MYLAN PHARMACEUTICALS INC.,
`Petitioners
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`___________________
`
`
`Inter Partes Review IPR2014-005491
`
`U.S. Patent No. 6,316,023
`
`
`PETITIONERS’ MOTION TO SEAL PORTIONS OF PETITIONERS’
`RESPONSE TO PATENT OWNERS’ MOTION FOR OBSERVATIONS ON
`CROSS-EXAMINATION OF DR. AGIS KYDONIEUS
`
`
`1
`Case IPR2015-00265 has been joined with this proceeding.
`
`
`
`
`
`
`
`
`Pursuant to the Office Patent Trial Practice Guide (Federal Register, Vol. 77,
`
`No. 157, Aug. 14, 2012), 37 C.F.R. § 42.14 and the Stipulated Protective Order
`
`(Ex. 2056), Petitioner Noven Pharmaceuticals, Inc. (“Noven”), respectfully
`
`submits this motion to seal limited portions of Petitioners’ Response to Patent
`
`Owners’ Motion for Observations on Cross-Examination of Dr. Agis Kydonieus
`
`(“Petitioners’ Response”), which reflect Patent Owners’ confidential information.
`
`The redacted portions of Petitioners’ Response reflect Patent Owners’ confidential
`
`information in Exhibits 1033, 1034, 1035, and 1036 that were previously filed
`
`under seal.
`
`The Patent Trial Practice Guide provides that “[t]he rules aim to strike a
`
`balance between the public’s interest in maintaining a complete and
`
`understandable file history and the parties’ interest in protecting truly sensitive
`
`information.” 77 FED. REG. 48756, 48760 (Aug. 14, 2012). “The rules identify
`
`confidential information in a manner consistent with Federal Rule of Civil
`
`Procedure 26(c)(1)(G), which provides for protective orders for trade secret or
`
`other confidential research, development, or commercial information.” Id.
`
`Patent Owners previously identified Exhibits 1033, 1034, 1035, and 1036 as
`
`containing sensitive confidential research and development information, and
`
`explained that such information has not previously been published or made public.
`
`(Paper 29 at 3-5.)
`
`
`
`1
`
`
`
`
`
`Therefore for the reasons set forth in Patent Owners’ Paper 29, Noven
`
`moves to seal the portions of Petitioners’ Response containing substantive
`
`reference to the above exhibits. Consistent with this motion, Noven will file a
`
`sealed version of Petitioners’ Response as well as a public version redacting
`
`substantive reference to the above exhibits.
`
`For the foregoing reasons good cause exists for sealing those portions of
`
`Petitioners’ Response that substantively refer to the above-listed exhibits.
`
`
`
`Dated: May 12, 2015
`
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Michael K. Levy/
`Steven J. Lee (Reg. No. 31,272)
`Michael K. Levy (Reg. No. 40,699)
`KENYON & KENYON LLP
`One Broadway
`New York, NY 10004-1007
`Tel: 212-425-7200
`Fax: 212-425-5288
`
`Counsel for Petitioner Noven Pharmaceuticals,
`Inc.
`
`2
`
`
`
`CERTIFICATE OF SERVICE
`
` I
`
`
`
` certify pursuant to 37 C.F.R. §42.6(e) that a copy of the foregoing
`
`Petitioners’ Motion to Seal Portions of Petitioners’ Response to Patent Owners’
`
`Motion for Observations on Cross-Examination of Dr. Agis Kydonieus was served
`
`electronically on May 12, 2015 to counsel for Patent Owners at the following
`
`email address: ExelonPatchIPR@fchs.com.
`
`
`
`Dated: May 12, 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Michael K. Levy/
`Michael K. Levy (Reg. No. 40,699)
`KENYON & KENYON LLP
`One Broadway
`New York, NY 10004-1007
`Tel: 212-425-7200
`Fax: 212-425-5288
`Counsel for Petitioner Noven Pharmaceuticals,
`Inc.
`
`1
`
`